{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040564","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.074170+00:00","generated_at":"2026-06-11T22:49:04.551628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium Q2 2023 net loss narrows to $3.3M; cash $48.4M; stock repurchase authorized","bullets":["Revenue of $9.1M from Ono partnership; net loss $0.10/sh vs $0.41/sh loss year ago.","Cash and investments $48.4M at June 30; fully prepaid and retired debt facility.","Authorized $7.5M stock repurchase program; cash runway expected into 2025.","Promoted Dr. Maple Fung to Chief Medical Officer; EQ101 alopecia areata data due 2H 2023.","Ono option for itolizumab could bring ~$35M; EQUALISE lupus nephritis topline early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040564","json":"https://secwatch.observer/filing/0000950170-23-040564.json","markdown":"https://secwatch.observer/filing/0000950170-23-040564.md","text":"https://secwatch.observer/filing/0000950170-23-040564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/0000950170-23-040564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023040564/eq-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:49:04.551628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}